Formulation development and Optimization of Diclofenac Sodium Extended release Matrix tablets as per USP standards.

Authors

  • S Edavalath Pharmaceutics Research Laboratory. Nehru College of Pharmacy (India)
  • M Shan Pharmaceutics Research Laboratory. Nehru College of Pharmacy (India)

Keywords:

Diclofenac sodium, Extended release matrix tablet, Optimization, Drug release kinetics

Abstract

Aim: To formulate Diclofenac sodium extended release tablets as per the standards given for extended release tablets of Diclofenac sodium in USP.

Materials and Methods: The extended release tablets of Diclofenac sodium was prepared by using different concentration of polymers such as hydroxyl propyl methyl cellulose sodium K4M (HPMC K4M) and hydroxyl propyl methyl cellulose sodium K15M (HPMC K15M). The drug polymer interactions were studied by using Fourier transform infrared (FT-IR) spectroscopy. The in vitro drug release and drug release kinetic studies of all the formulations were performed and compared with the marketed product Fenac SR. The optimization done by considering the factors such as drug release limit given as per USP standard, t50% and release exponent (‘n’ value as per Korsmeyer Peppas).

Results and Conclusions: The FT-IR spectroscopy studies revealed that there was no interaction between drug and excipients. The drug release observed that it depends on the concentration and nature of the rate controlling polymers used. The ANOVA studies revealed that the formulations show significant effect in drug release. The optimization studies proved that the formulation containing drug, polymer (HPMC K4M) ratio of 1:1.5 (Formulation M3) is the most satisfactory formulation. The stability studies proved that the formulation is stable.

Downloads

Download data is not yet available.

References

Chien YW. Novel drug delivery systems. 2nd ed. New York: Marcel Dekker; 2005.p.139-196.

Banker GS, Rhodes CT. Modern pharmaceutics. 4th ed. New York: Marcel Dekker; 2007.p.501-13,727-752.

Gandhi R, Kaul CL, Panchagnula R. Pharmacokinetic evaluation of an azithromycin controlled release dosage form in healthy human volunteers: a single dose study. Int J Pharm. 2004;270:1-8.

Robinson JR, Vincent H. L. T. Controlled drug delivery fundamentals and applications. 2nd ed. New York: Marcel Dekker; 2005.p.373-403.

Chowdary KPR, Mohapatra P, Krishna MN. Evaluation of olibanum and its resin as rate controlling matrix for controlled release of diclofenac. Indian J Pharm Sci. 2006; 68(4):497-500.

Punna RR, Sindhura G, Ranendra NS. Design and study of lamivudine oral controlled release tablets. AAPS Pharm Sci Tech. 2007;8(4):E1-E9.

Hamdy A, Ossama Y A, Hesham S. Formulation of controlled release baclofen matrix tablets: influence of some hydrophilic polymers on the release rate and in vitro evaluation. AAPS Pharm Sci Tech. 2007;8(4):E1-E11.

Patrick JS. Martin’s physical pharmacy and pharmaceutical sciences. 5th ed. New Delhi: Wolters Kluwer health (India) pvt.ltd; 2006.p.137,553-557.

Raghuram RK, Srinivas M, Srinivas R. Once-daily sustained release matrix tablets of nicorandil: formulation an in vitro evaluation. AAPS Pharm Sci Tech. 2003; 4(4):1-9.

Rani M, Mishra B. Comparative in vitro and In vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium. AAPS Pharm Sci Tech. 2004;5(4):1-7.

Ayhan S, Yalcin O, Askin I¸ Imer. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium. Farmaco. 2005;60:171-177.

Makhija SN, Vavia PR. Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine I. Cellulose acetate as a semi permeable membrane. J Control Release. 2003;89:5-18.

Donald LW. Hand book of pharmaceutical controlled release technology. New York: Marcel Dekker; 2000.p.183-8, 225-54, 431-436.

Kanagale P, Lohray BB, Misra A, Davadra P, Kini R. Formulation and optimization of porous osmotic pump–based controlled release system of oxybutynin. AAPS Pharm Sci Tech. 2007;8(3):E1-E7.

The United States Pharmacopeial Convention. Diclofenac sodium extended release tablets. Revision Bulletin Official Monographs / Diclofenac Official 2009 Mar.p.1-2.

Downloads

Published

2012-03-20

How to Cite

1.
Edavalath S, Shan M. Formulation development and Optimization of Diclofenac Sodium Extended release Matrix tablets as per USP standards. Ars Pharm [Internet]. 2012 Mar. 20 [cited 2024 Jul. 22];53(1):05-10. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4656

Issue

Vol. 53 No. 1 (2012)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).